Evotec

Evotec ROA

The Return on Assets (ROA) of Evotec (EVT.DE) as of Nov 16, 2026 is -5.82 %. In the previous year, Return on Assets (ROA) was -10.25 % — a change of -43.24% (higher).

ROA

-5.82 %

YoY

-43.24%

Last updated:

In 2025, Evotec's return on assets (ROA) was -5.82 %, a -43.24% increase from the -10.25 % ROA in the previous year.

The Evotec ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2018
10.90 EUR
Jan 1, 2019
3.23 EUR
Jan 1, 2020
0.43 EUR
Jan 1, 2021
9.64 EUR
Jan 1, 2022
-7.78 EUR
Jan 1, 2023
-3.73 EUR
Jan 1, 2024
-10.25 EUR
Jan 1, 2025
-5.82 EUR
The Evotec ROA history
YEARROAYoY
-5.82 %-43.24%
-10.25 %+175.21%
-3.73 %-52.13%
-7.78 %-180.71%
9.64 %+2,146.73%
0.43 %-86.72%
3.23 %-70.37%
10.90 %+199.97%
3.64 %-53.60%
7.84 %+36.88%
5.72 %-284.24%
-3.11 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Evotec Stock analysis

What does Evotec do? Evotec SE is a biotechnology company based in Hamburg that specializes in the development of drug compounds for the pharmaceutical and biotech industries. The company was founded in 1993 as part of a research project at the University of Hamburg and has since become one of the leading drug discovery and development companies globally. Evotec's business model is based on collaborating with its customers, primarily large pharmaceutical companies, to develop new and innovative drugs. Evotec offers its extensive expertise in drug discovery and acts as a service provider. The company has modern laboratories equipped with state-of-the-art scientific methods and technologies. Customers benefit from the scientists' years of experience and collaboration with renowned academic institutions worldwide. Evotec operates in the Discovery, Development, and Manufacturing segments, providing a wide range of services to its customers. In the Discovery segment, the focus is on identifying drug candidates and preclinical development of drugs using advanced technologies and research methods. In the Development segment, Evotec supports its customers in the planning, execution, and analysis of clinical trials. The close collaboration with customers allows Evotec's scientists to respond quickly and effectively to feedback and requirements. The Manufacturing segment involves the industrial production of drugs. Evotec offers a broad range of products, including both its own and customer-requested drug compounds. One example is the drug DiaPep277 for the treatment of Type 1 diabetes. DiaPep277 was developed by Evotec in collaboration with Israeli company Andromeda Biotech and is now distributed by Teva Pharmaceuticals. Another example is the drug EVT307, which was developed by Evotec in collaboration with pharmaceutical company Boehringer Ingelheim and is currently being tested in Phase II clinical trials for the treatment of schizophrenia. Evotec's success is also based on its expertise in the production of small molecules. Small molecules are drug compounds characterized by their small size and highly specific binding to target proteins. In contrast, the production of large molecules such as antibodies or biologics is more complex and expensive in development due to their size. Evotec's success story continues: In 2019, the company achieved record results, increasing its revenue by 23 percent to 446.4 million euros. The number of employees has also steadily grown in recent years and now exceeds 3,000 employees worldwide. Evotec is considered one of the most successful biotechnology companies in Europe today. Evotec is one of the most popular companies on Eulerpool.

ROA Details

Understanding Evotec's Return on Assets (ROA)

Evotec's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Evotec's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Evotec's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Evotec’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Evotec stock

Return on Assets (ROA) of Evotec is -5.82 % in 2025.

Return on Assets (ROA) of Evotec changed from -10.25 % to -5.82 %, representing a -43.24% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Evotec since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Evotec with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Evotec

All Key Metrics — Evotec